Ivanivska T S, Sklyarenko L M, Zavelevich M P, Philchenkov A A, Koval S V, Polishchuk A S, Gluzman D F
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
Exp Oncol. 2019 Sep;41(3):207-209. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13492.
According to the modern concept, leukemic stem cells (LSC) in acute myeloid leukemia (AML) are distinct from the bulk of leukemic cells in bone marrow and peripheral blood of AML patients. Nevertheless, LSC are responsible for managing all the hierarchy of the bulk of leukemic blast populations. This mini-review provides brief information on the distinctive features of LSC and blast cells in cytologically recognized types of AML. The study of different phenotypes of LSC and blast cells in AML with the aid of up-to-date flow cytometric techniques is important both for the deep insight into the mechanisms of leukemogenesis and development of novel strategies of target therapy. The urgent need for extending the diagnostic panel of monoclonal antibodies used for diagnosing AML is beyond doubt.
根据现代概念,急性髓系白血病(AML)中的白血病干细胞(LSC)与AML患者骨髓和外周血中的大多数白血病细胞不同。然而,LSC负责管理大多数白血病母细胞群体的整个层级结构。这篇小型综述提供了关于细胞学上已识别的AML类型中LSC和母细胞的独特特征的简要信息。借助最新的流式细胞术技术研究AML中LSC和母细胞的不同表型,对于深入了解白血病发生机制和开发新的靶向治疗策略都很重要。毫无疑问,迫切需要扩大用于诊断AML的单克隆抗体诊断组。